Summarized by Masters of Longevity from PR Newswire.
Market analysis details accelerating development and commercial interest in KRAS-targeted cancer therapies across multiple tumor types and mutation subtypes.
Key Takeaways
- Multiple KRAS inhibitors from companies including Roche, Eli Lilly, Merck, and Genfleet are advancing through clinical development.
- Olomorasib received FDA Breakthrough Therapy and Orphan Drug designations for specific KRAS G12C lung cancer and later got BTD for pancreatic cancer.
- Calderasib (MK-1084) received FDA Breakthrough Therapy Designation for first-line treatment of PD-L1–expressing KRAS G12C NSCLC.
